[{"Assets_0_Q2_USD":507130000.0,"CommonStockSharesOutstanding_0_Q2_shares":38290876.0,"EarningsPerShareBasic_1_Q2_USD":-0.34,"EarningsPerShareBasic_2_Q2_USD":-0.63,"EarningsPerShareDiluted_1_Q2_USD":-0.34,"EarningsPerShareDiluted_2_Q2_USD":-0.63,"NetIncomeLoss_1_Q2_USD":-13229000.0,"NetIncomeLoss_2_Q2_USD":-24319000.0,"StockholdersEquity_0_Q2_USD":295829000.0,"WeightedAverageNumberOfDilutedSharesOutstanding_1_Q2_shares":39041145.0,"WeightedAverageNumberOfDilutedSharesOutstanding_2_Q2_shares":38545982.0,"WeightedAverageNumberOfSharesOutstandingBasic_1_Q2_shares":39041145.0,"WeightedAverageNumberOfSharesOutstandingBasic_2_Q2_shares":38545982.0,"Ticker":"TVTX","CIK":"1438533","name":"RETROPHIN, INC.","OfficialName":"Travere Therapeutics Inc. Common Stock","form":"10-Q","period":"20170630","fy":"2017.0","fp":"Q2","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"1905907401.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"nan","filed":"20170809"}]